1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Catalyst Pharmaceutical Screen Patients For Phase II Clinical Trial Of Meth Addiction

By Alfa, Jul 7, 2008 | |
  1. Alfa
    Catalyst Pharmaceutical Screen Patients For Phase II Clinical Trial Of Meth Addiction Drug
    Monday, July 07, 2008; Posted: 01:07 AM

    July 7, 2008 (FinancialWire) Catalyst Pharmaceutical Partners Inc. said that it has begun enrollment for its U.S. Phase II clinical trial of a treatment for patients addicted to methamphetamine.

    The development-stage pharmaceutical company said CPP-109 inhibits psychostimulant-induced dopamine release and is its version of vigabatrin, which is used to treat epilepsy and infantile spasms in some parts of the world, but is not approved for use in the U.S.

    Catalyst said it expects to immediately begin screening patients for inclusion in the trial and for results to be available during the summer of 2009.

    The company plans to enroll 180 methamphetamine-addicted patients at 15 treatment clinical centers in the U.S. Patients will be treated for three months, with a three-month follow-up. The goal of the study is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo-treated subjects will be methamphetamine-free during their last two weeks of treatment.

    Shares of Catalyst rose 46 cents to close at $3.53 Thursday. The 52-week high was $4.20 on July 19 and the 52-week low was $2.06 on November 16.

    http://www.tradingmarkets.com/.site/news/Stock News/1737534/

Comments

To make a comment simply sign up and become a member!